|AFMR Website||Meetings/Events Calendar||Submit a JIM manuscript|
Samrat U. Das, MD
As summer continues, I hope you and your families are taking some time for rest and recreation.
During this season, AFMR leadership is working on issues of importance to our members — 2022 regional and national meetings, membership, awards, and AFMR involvement in FASEB (Federation of American Societies for Experimental Biology).
Regional and national meetings are in the planning stages with dates and locations set for some. Others are still to be determined.
Recruitment of New AFMR Members
National leadership is working with regional councils to grow AFMR membership. Councils are reaching out to DO schools and HBCU (historically black colleges and universities) medical schools to attract a wider diversity of regional councilors. One of the roles of regional councilor is to promote AFMR membership and meetings at the councilor's institution. Zanthia Wiley, MD, a National Council councilor-at-large has been named chair elect of the AFMR membership committee. She will be representing national leadership and the committee at regional council meetings to promote AFMR membership goals and objectives.
The 2020 medical journal Impact Factors were announced on June 20, 2021, and the Journal of Investigative Medicine (JIM) saw an increase to 2.895 — 25 percent over 2019.
JIM is the official journal of AFMR. Published eight times a year, it became an online only journal in 2021.
JIM ranks 59 out of 169 journals in the Medicine, General and Internal category, and it is 91 out of 140 titles in the Medicine, Research and Experimental category.
The 2020 Impact Factor citation period took place under JIM former editor-in-chief and current editor emeritus Michael J. McPhaul, MD.
A JIM subscription is one of many valuable benefits of an AFMR membership. Members also pay no page charges for published manuscripts. Don't miss out on any issues of this PubMed journal. Make sure your membership is current.
Do you have a high-quality original article, editorial or review in the areas of basic, clinical, and translational medical research? JIM encourages submissions from AFMR members. Learn more.
Abstract submissions are now open for the AFMR Western and Southern regional meetings.
AFMR members whose abstracts are chosen for presentation are eligible for the Henry Christian Award. Check to make sure your membership is current. Research travel award opportunities are also available.
Western Medical Research Conference
The Western Medical Research Conference will be taking place from January 20 -22, 2022 in Carmel, CA.
Abstract Deadline: Friday, September 24, 2021, 11:59 PT
Learn more and submit.
Southern Regional Meeting
The Southern Regional Meeting will be taking place from February 10-12, 2022 in New Orleans, LA.
Abstract Deadline: Friday, October 8, 2021, 11:59 ET
Submissions open August 6, 2021. Learn more and submit.
In the past several months, AFMR has added more benefits for members in good standing. Check your membership status today and renew, if necessary, so you can take advantage of these and the many other advantages of AFMR membership — including subscriptions to The Journal of Investigative Medicine (JIM) and The Journal of Investigative Medicine - High Impact Case Reports (JIM-HICR).
Looking for a mentor? The AFMR Mentorship Program now includes a list of mentors, including information on their specialty, a bio and email link. All are available for Zoom sessions.
Promote Your Article/Talk on AFMR Social Media
AFMR will spread the word about your recent publication/talk on AFMR social media. Promote your accomplishment by filling out the Promote Your Publications/Talks on AFMR Social Media form on the Members Only section of the AFMR website.
Remember: Your dues must be up to date to take advantage of these opportunities!
The full program and presentations from the Eastern Regional Meeting are now online. Access is free.
Registration is required. Those who have already registered for a Virtual Education Portal presentation only need to log in. The meeting videos are compatible with mobile devices, tablets, laptops and desktops.
View the Eastern Conference proceedings.
Southern and Western Meeting Proceedings Available Through September
There's still time to view the programs/presentations from the 2021 Southern and Western Regional Meetings. They will remain online until September 30, 2021.
The July issue of AFMR Insights included an article about the controversial decision by the FDA approving the Alzheimer's drug Aducanumab (Aduhelm). It linked to two opinion pieces — one by former AFMR National Council member and current Eastern Region Section councilor Allison Reiss, MD, who is an Alzheimer’s researcher. Since then, the debate has continued.
The New York Times published an article on July 20th detailing "How an Unproven Alzheimer's Drug Got Approved."
FDA Reversed Recommendation on Who Should Receive Aducanumab
In early July, the FDA reversed its original recommendation that Aducanumab should be given to all Alzheimer's patients, stating that the drug only should be prescribed for those with mild memory or thinking problems. Read coverage of the reversal from The New York Times. View the revised drug label and prescribing information.
Acting FDA Commissioner Called for an Inspector General Review of FDA Interactions with Biogen, Maker of Aducanumab
On July 9th, acting FDA commissioner Janet Woodcock requested that the agency's inspector general do an "independent review and assessment" of the agency's communications with Aducanumab's maker, the drug company Biogen. She made her letter to the inspector general public on Twitter, explaining that she asked for the review because of "ongoing interest and questions" about the drug. An article in the Washington Post detailed her request and the Aducanumab controversy.
The Cleveland Clinic & Mount Sinai Health System Decided Not to Dispense the Drug for Their Patients
The Cleveland Clinic and Mount Sinai Health System in New York City have decided not to dispense Aducanumab for their patients. The drug’s maker put out a statement, saying “Biogen continues to stand 100% behind Aduhelm and the clinical data that supported approval. If any patient is denied access to care, we encourage them to contact us for help as we remain committed to supporting access to Aduhelm for all appropriate patients.”
American Neurological Association Executive Committee Told Members Drug Should Not Have Been Approved
In a statement, the American Neurological Association Executive Committee told members that "...based on the clinical evidence, Aduhelm should not have been approved at this time." View statement.
The American Association of Medical Colleges (AAMC) states it is dedicated to "...advancing medical education to meet society’s evolving needs; making patient care safer, more affordable, and more equitable; and sustain the discovery of scientific advances."
It does so in four primary mission areas: medical education, healthcare, medical research, and community collaborations.
As part of its research/community engagement initiative, AAMC provides a list of health equity grants and funding opportunities. The list is updated weekly.
FASEB's new president — Patricia L. Morris, PhD — took office on July 1. Dr. Morris is a molecular endocrinologist and pharmacologist. She is guest investigator at the Laboratory of RNA Molecular Biology at The Rockefeller University and a senior scientist at Chromocell.
Previously, she was Executive Director of Biomedical Research and Development and senior scientist at the Reproductive Health Program of the Population Council. She also served as associate editor of the FASEB Journal.
Other newly elected members of the FASEB board include Kevin C. Kregel, PhD (president-elect), Mary-Ann Bjornsti, PhD (Vice President for Science Policy), Beth A. Garvy, PhD (Vice President-elect for Science Policy), Cherié L. Butts, PhD (treasurer-elect), and Vijay P. Kale, MVSc, PhD, DABT, ERT (early career representative)
Learn more about Dr. Morris and other new FASEB board members.
Research!America CEO and President Mary Woolley has issued a statement regarding the Cures 2.0 Act discussion draft. This legislation has been proposed by US House of Representatives members Diana DeGette (D-CO) and Fred Upton (R-MI), who released the draft for review.
The bill is aimed at accelerating medical and public health progress and builds on their 21st Century Cures Act, signed into law in 2016. That legislation has helped find solutions for the most urgent health threats facing the nation.
View the Cures 2.0 discussion draft.
The topic of Diversity, Equity and Inclusion (DEI) in medical research is not new. Renewed interest in the issue has been sparked by the equity issues raised by the coronavirus pandemic. Two online pieces provide different perspectives.
One is an overview on DEI with curated resources from the Health Research Alliance (HRA). The HRA is a "collaborative member organization of nonprofit research funder...committed to maximizing the impact of biomedical research to improve human health." HRA has a dedicated Research Workforce and Early Career Development Working Group aimed at assisting its members to "...build a diverse, motivated, and committed research workforce."
HRA’s Diversity, Equity and Inclusion issue overview discusses its activities and provides links to previous undertakings in the field.
HRA is hosting a "Reimagining Biomedical Research for a Healthier Future Symposium" on September 23, 2021 from noon to 1:00 pm ET. The event will discuss ideas proposed by the winners of its Reimagine Biomedical Research for a Healthier Future Essay Challenge. Learn more about the essays and symposium.
The Forbes Technology Council posted an article about "How Digital Technology Can Increase Diversity, Equity and Inclusion in Medical Research." The piece is authored by Praduman Jain, a council member and CEO/Founder of Vibrent Health, a digital health technology company.
AFMR is taking its social media footprint to the next level.
We need social media savvy members to help us promote AFMR national and regional news and events, our journals, and member news.
Become a member of the new AFMR Social Media Committee, chaired by Ricardo Correa, MD, AFMR Western chair elect. We’re looking for representation for all AFMR regions.
As a social media committee member, you’ll help plan the AFMR social media approach and be part of the posting team for one of the AFMR platforms (Twitter, LinkedIn and Facebook). And your participation in a national-level AFMR committee will be a good addition to your resume!
Send us an email if you're interested.
||Journal of Investigative Medicine
|American Federation for Medical Research
JIM is now an online only journal.
Announcing JIM's COVID Collection: Articles from the JIM archive on pandemic-related research.
Hepatitis C Month
Guest: Don C. Rockey, MD, Medical University of South Carolina, Charleston, SC
August 3, 2021
Impact and role of pulmonary embolism response teams in venous thromboembolism associated with COVID-19 — ✔ Editor's Choice
Mateo Porres-Aguilar, Victor F Tapson, Belinda N Rivera-Lebron, Parth M Rali, David Jiménez, Mateo Porres-Muñoz, Sarah Barraza, Oscar C Muñoz, Debabrata Mukherjee
Comparing patient characteristics and outcomes in type 1 versus type 2 diabetes with diabetic ketoacidosis: a review and a propensity-matched nationwide analysis
Hafeez Shaka, Farah Wani, Zain El-Amir, Dushyant Singh Dahiya, Jagmeet Singh, Ehizogie Edigin, Precious Eseaton, Asim Kichloo
Experimental study on alleviating atherosclerosis through intervention of mitochondrial calcium transport and calcium-induced membrane permeability transition
Sisi Chen, Jianing Wang, Lei Zhang, Hao Xia
Non-surgical animal model of gastroesophageal reflux disease by overeating induced in mice
Nu-Ri IM, Byoungjae Kim, Kwang-Yoon Jung, Tae Hoon Kim, Seung-Kuk Baek
Utility of serum neuropilin-1 and angiopoietin-2 as markers of hepatocellular carcinoma
Muhammad Tarek Abdel Ghafar, Reham A Elkhouly, Mohammed H Elnaggar, Mohamed M Mabrouk, Sara A Darwish, Reham L Younis, Rasha A Elkholy
Effects of human immunodeficiency virus status on symptom severity in influenza-like illness in an otherwise healthy adult outpatient cohort
Rhonda E Colombo, Christina Schofield, Stephanie A Richard, Mary Fairchok, Wei-Ju Chen, Patrick J Danaher, Tahaniyat N Lalani, Michelande Ridoré, Ryan C Maves, John C Arnold, Anuradha Ganesan, Brian Agan, Eugene V Millar, Christian Coles, Timothy H Burgess
COVID-19 reinfection: a rapid systematic review of case reports and case series
Jingzhou Wang, Christopher Kaperak, Toshiro Sato, Atsushi Sakuraba
Autophagy and cancer metastasis: a Trojan horse
Javad Alizadeh, Shahrokh Lorzadeh, Saeid Ghavami
Letters to the Editor
Correlation of rate of serum albumin decline with other acute phase reactants and effect of current treatment options on serum albumin level in COVID-19
Simrat Kaur Batth
Sensational media reporting is common when describing COVID-19 therapies, detection methods, and vaccines
Ryan Ottwell, Madison Puckett, Taylor Rogers, Savannah Nicks, Matt Vassar
Check out JIM-HICR's new COVID-19 Collection of cases focusing on pandemic-related issues.
Massive Ischemic Strokes in a Young Patient with Severe Coronavirus Disease 2019 Pneumonia
Stroke is an identified sequela of severe coronavirus disease 2019 (COVID-19) infection. While the pathophysiology remains poorly understood, endothelial dysfunction and intravascular thrombosis secondary to sepsis-induced hypercoagulability likely increase the risk of stroke. This report describes the rare case of an otherwise healthy 42-year-old male who developed large bilateral ischemic infarcts during admission for severe hypoxemic respiratory failure secondary to COVID pneumonia. This report adds to scarce literature describing massive cerebrovascular injury in COVID patients and emphasizes the importance of increased clinical suspicion for stroke in patients who exhibit acute change in mental status or motor function, as well as rapid clinical deterioration.
The Ugly Side of Colchicine
We report a rare case of a 32-year-old male who ingested 32.4 to 54 mg of colchicine and presented after 44 hours. He developed progressive multiple organ failure with shock, acute kidney failure, troponemia, pancytopenia, absolute neutropenia, disseminated intravascular coagulation, acute liver failure, rhabdomyolysis, and lactic acidosis. He also developed electrolyte abnormalities and refractory hypoglycemia. Initial treatment consisted of activated charcoal, fluids, and broad-spectrum antibiotics with supportive treatment of mechanical ventilation, hemodialysis, vasopressors, N-acetylcysteine, colony-stimulating factors, and blood products. Literature shows potential benefit of colchicine-specific Fab fragments for acute toxicity with limited studies and is not currently available in the United States. Further research for N-acetylcysteine protocol for acute liver failure in colchicine toxicity and potential use of colchicine-specific Fab fragments is needed. Our case demonstrates the importance of early use of activated charcoal for ingestion overdose with the incorporation of poison control into multidisciplinary team for coordinated patient care.
Rhabdoid Meningioma Metastases Cervical Lymph Nodes: A Rare Clinical Case Report and Treatment Outcome
Meningioma is the most common central nervous system tumor that usually behaves benignly and has a good prognosis after treatment with tumor gross resection and with or without adjuvant therapy. Malignancy in meningioma is very rare and extracranial metastasis to cervical lymph nodes is even rarer. We report a case of a 40-year-old woman diagnosed with metastatic rhabdoid meningioma. She had recurrent primary disease and metastasis to bilateral cervical lymph nodes. She previously had intracranial tumor twice resected. We also review relevant, previously published cases in the literature.
Recurrent Priapism from Cabergoline and Bromocriptine in a Hypogonadal Man with Prolactinoma
Dopamine agonists are generally well tolerated and represent the first-line therapy for prolactinomas. We report a case of a 20-year-old man with a macroprolactinoma who developed recurrent priapism with cabergoline and bromocriptine. Transsphenoidal pituitary adenoma resection was done with normalization of the prolactin level. Priapism is a rare side effect of dopamine agonists that warrants discontinuation of therapy. Patients should be educated about this potential side effect at the time of prescribing the medication.
The World Health Organization (WHO) has a dedicated COVAX website providing information on country vaccine readiness and delivery, workstream, FAQs, updates, data and more.
COVAX is a partnership of CEPI (Coalition for Epidemic Preparedness Innovations), GAVI (The Vaccine Alliance), and the WHO. UNICEF serves as a vaccine delivery partner. The PAHO (Pan American Health Organization) Revolving Fund is COVAX’s recognized procurement representative in the Americas.
The site also includes the latest news about international vaccine distribution through the COVAX network.
The World Health Organization (WHO) has a dedicated page devoted to global research on coronavirus.
The page includes links to:
News and information on COVID-19 is constantly changing.
The Johns Hopkins coronavirus resource center now includes a vaccine tracker, as well as separate pages covering:
Its Interactive Map is updated throughout the day.
|Meeting dates for 2022 AFMR Regional and Affiliate Meetings are chronologically listed below.
Dates are not yet set for the Eastern and Midwestern Clinical and Translational Research Meeting. Check this section monthly for updates.
Visit the AFMR website to get the latest on 2022 AFMR meetings and events.
Theo Trandafirescu, MD
VP of Meetings & Programs
Western Regional Meeting
January 20-22, 2022
Abstract Deadline: September 24, 2021
Southern Regional Meeting
February 10-12, 2022
Abstract Deadline: October 8, 2021
New Orleans, LA
Experimental Biology 2022
April 2-5, 2022
Translational Science 2022
April 20-22, 2022